Skip to main content
. 2017 Dec 4;9(6):6752–6762. doi: 10.18632/oncotarget.22886

Figure 1.

Figure 1

Kaplan-Meier survival curves for (A) progression-free survival and (B) overall survival, according to baseline plasma YKL-40 levels. BEV, bevacizumab; Plb, placebo; Q1, lowest quartile of plasma YKL-40 levels.